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Aims: Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of type
2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have
reported risk of below-knee lower extremity (BKLE) amputation. This study examined the real-
world comparative effectiveness within the SGLT2i class and compared with non-SGLT2i anti-
hyperglycaemic agents.
Materials and methods: Data from 4 large US administrative claims databases were used to
characterize risk and provide population-level estimates of canagliflozin's effects on hospitaliza-
tion for heart failure (HHF) and BKLE amputation vs other SGLT2i and non-SGLT2i in T2DM
patients. Comparative analyses using a propensity score–adjusted new-user cohort design
examined relative hazards of outcomes across all new users and a subpopulation with estab-
lished cardiovascular disease.
Results: Across the 4 databases (142 800 new users of canagliflozin, 110 897 new users of
other SGLT2i, 460 885 new users of non-SGLT2i), the meta-analytic hazard ratio estimate for
HHF with canagliflozin vs non-SGLT2i was 0.39 (95% CI, 0.26-0.60) in the on-treatment analy-
sis. The estimate for BKLE amputation with canagliflozin vs non-SGLT2i was 0.75 (95% CI,
0.40-1.41) in the on-treatment analysis and 1.01 (95% CI, 0.93-1.10) in the intent-to-treat anal-
ysis. Effects in the subpopulation with established cardiovascular disease were similar for both
outcomes. No consistent differences were observed between canagliflozin and other SGLT2i.
Conclusions: In this large comprehensive analysis, canagliflozin and other SGLT2i demonstrated
HHF benefits consistent with clinical trial data, but showed no increased risk of BKLE amputa-
tion vs non-SGLT2i. HHF and BKLE amputation results were similar in the subpopulation with
established cardiovascular disease. This study helps further characterize the potential benefits
and harms of SGLT2i in routine clinical practice to complement evidence from clinical trials and
prior observational studies.
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1 | INTRODUCTION
Canagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i)
that is approved for the treatment of type 2 diabetes mellitus (T2DM).
In the CANagliflozin cardioVascular Assessment Study (CANVAS) Pro-
gram that enrolled patients with T2DM and established cardiovascular
disease or high cardiovascular risk, canagliflozin reduced the risk of
major adverse cardiovascular events, hospitalization for heart failure
(HHF) and death from cardiovascular causes or HHF relative to pla-
cebo, while increasing the risk of below-knee lower extremity (BKLE)
amputation.1 Multivariable analyses showed that the risk of amputa-
tion with canagliflozin was largely driven by known risk factors for
amputation (ie, prior amputation, peripheral vascular disease, male
sex, neuropathy, HbA1c > 8.0% and presence of cardiovascular dis-
ease), although canagliflozin treatment increased the risk of amputa-
tion independent of other risk factors.2
The EMPA-REG OUTCOME trial showed a reduction in the risk
of major adverse cardiovascular events, HHF and all-cause mortality
with empagliflozin vs placebo; there was no report of an increased risk
of amputation with empagliflozin.3,4 Findings from observational stud-
ies have confirmed the observed benefits of SGLT2i on HHF in clinical
trials.5,6 Two retrospective database studies compared the risk of
amputation with SGLT2i and non-SGLT2i. No difference in rate of
amputation was seen among all new users in a privately insured, gen-
eral population with T2DM, 21% with established cardiovascular
disease,7 while an increased risk was seen in a subpopulation of
patients with T2DM and established cardiovascular disease in the
Department of Defense Military Health System according to the
EASEL study.8 No study has directly compared drugs in the SGLT2i
class to determine if there is a class effect for safety and
effectiveness.
This study, OBSERVE-4D, examined the comparative effects of
canagliflozin vs other SGLT2i and non-SGLT2i antihyperglycaemic
agents (AHAs) on the risk of HHF and BKLE amputation in patients
with T2DM, overall and within the subpopulation of patients with
established cardiovascular disease, across 4 US administrative claims
databases.
2 | MATERIALS AND METHODS
A series of analyses was conducted within this population-level
effect estimation study following a retrospective comparative
cohort design across 4 observational databases. The study was reg-
istered on ClinicalTrials.gov (NCT03492580), and the protocol was
reviewed by the FDA prior to study execution. All analyses were
pre-planned, with primary and sensitivity analyses pre-specified as
part of the protocol; no post hoc sensitivity analyses were per-
formed. The full protocol, including all diagnoses, procedures and
drug codes used to define the cohorts, as well as all analytic
source codes to execute the study, has been made publicly avail-
able at https://github.com/OHDSI/StudyProtocols/tree/master/
AhasHfBkleAmputation.
2.1 | Data sources
De-identified patient-level data from 4 US administrative claims data-
bases were used for this study: (1) Truven MarketScan® Commercial
Claims and Encounters (CCAE), a medical and drug insurance claims
database of unique patients that includes active employees, early
retirees and their dependents insured by employer-sponsored plans;
(2) Truven MarketScan® Multi-state Medicaid (MDCD), an administra-
tive claims database that includes the pooled healthcare experience of
Medicaid enrollees from multiple states; (3) Truven MarketScan®
Medicare Supplemental Beneficiaries (MDCR), an administrative
health claims database for Medicare-eligible active and retired
employees and their Medicare-eligible dependents from employer-
sponsored supplemental plans; and (4) OptumInsight's Clinformatics®
Datamart (Optum), an administrative health claims database for mem-
bers who are fully insured in commercial plans or in administrative ser-
vices only and commercial Medicare.
2.2 | Exposure Cohorts
Six primary exposure cohorts of interest were defined as new users
of: (1) canagliflozin; (2) empagliflozin or dapagliflozin; (3) empagliflozin;
(4) dapagliflozin; (5) select non-SGLT2i, defined as any dipeptidyl
peptidase-4 inhibitor (DPP-4i), glucagon-like peptide-1 (GLP-1) recep-
tor agonist or other AHA (acarbose, bromocriptine, miglitol, nategli-
nide, repaglinide); and (6) all non-SGLT2i, defined as any DPP-4i, GLP-
1 receptor agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin
or other AHA.
Each exposure cohort was defined as the set of patients who had
a first exposure for the cohort-defining drug(s), with the first exposure
date (index date) occurring between April 1, 2013 and May 15, 2017,
who had at least 1 diagnosis of T2DM without any diagnosis of
T1DM or secondary diabetes on or any time before the index date,
and for whom there was no evidence of dispensing of the defining
drug in the required ≥365 days of prior continuous observation.
For each exposure cohort, risk was characterized across all new
users, as well as within the subpopulation of patients with established
cardiovascular disease, defined as having at least 1 diagnosis code for
a condition indicating cardiovascular disease, such as arteriosclerotic
vascular disease, cerebrovascular disease, ischemic heart disease or
peripheral vascular disease, or having undergone at least 1 procedure
indicating established cardiovascular disease, such as percutaneous
transluminal coronary angioplasty, coronary artery bypass graft or
revascularization, any time on or prior to the exposure start.
2.3 | Outcome ascertainment
This study examined 2 primary outcomes of interest: (1) HHF and
(2) BKLE amputation events. HHF was defined as all hospital admis-
sions with a primary diagnosis of heart failure, as identified by ICD-
9-CM and ICD-10-CM codes. BKLE amputation events were defined
as all new BKLE amputation procedures, as identified by CPT-4 or
ICD-9-PCS codes for amputation of lower leg, ankle, foot or toe,
excluding recent (within 30 days) revisions.
Additionally, 44 negative control outcomes, that is, conditions
believed not to be causally associated with any of the exposure
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cohorts based on product labeling, published literature and spontane-
ous adverse event reporting, which have been used in prior observa-
tional studies of canagliflozin,7 were selected as a statistical diagnostic
strategy to identify residual systematic error in the databases or study
design and to empirically calibrate P values for any systematic error
observed.9,10 For each negative control outcome, we assumed a priori
that the true hazard ratio (HR) was 1, and we applied the same analy-
sis designed for the outcomes of interest to each negative control out-
come, with the difference between the estimated HR of the negative
control and 1 representing an estimate of the systematic error present
for that outcome. Using these error estimates from all 44 negative
controls, we produced an empirical null distribution that reflects the
range of potential bias that may be present within the unknown out-
comes (eg, HHF and BKLE amputation) and used this distribution to
compute a calibrated P value for each outcome.
2.4 | Time-at-risk periods
Two primary time-at-risk periods were evaluated: (1) an on-treatment
period aimed at evaluating risk during the period in which an individ-
ual is exposed to the drug; and (2) an intent-to-treat period aimed at
evaluating overall risk after initiating treatment. The on-treatment
period was defined as the time from 1 day after exposure cohort start
date (ie, the date of first exposure to the cohort-defining drug/s) until
the exposure cohort end date, defined as the end of the first persis-
tent period of exposure, allowing for a 30-day gap between succes-
sive exposures until the final exposure record. This exposure cohort
end date represents the date the patient was expected to finish the
dispensed supply of the last drug dispensed, but censoring at the time
that any dispensing of a different non-metformin AHA was observed.
The intent-to-treat period was defined as the time from 1 day after
exposure cohort start date to the end of the patient's observation
period. Four additional time-at-risk variants were run for sensitivity
analyses, as defined in the protocol.
2.5 | Statistical analyses
Crude incidence rates of both outcomes were estimated within each
exposure cohort and pre-defined subgroups were estimated as the
number of individuals with the outcome during each time-at-risk win-
dow, divided by the total time-at-risk.
Population-level effect estimation analyses using a comparative
cohort design were applied for 7 pairwise comparisons and all associ-
ated subgroups therein, that is, new users of: (1) canagliflozin vs
empagliflozin or dapagliflozin; (2) canagliflozin vs empagliflozin; (3) cana-
gliflozin vs dapagliflozin; (4) canagliflozin vs any DPP-4i, GLP-1 receptor
agonist or other select AHA; (5) canagliflozin vs any DPP-4i, GLP-1
receptor agonist, TZD, SU, insulin or other select AHA; (6) empagliflozin
or dapagliflozin vs any DPP-4i, GLP-1 receptor agonist or other select
AHA; and (7) empagliflozin or dapagliflozin vs any DPP-4i, GLP-1 recep-
tor agonist, TZD, SU, insulin or other select AHA. Patients with an
observed outcome prior to index exposure were handled in 2 ways:
(1) time-to-first-post-index-event analysis, where hazards of an occur-
rence of outcome among all exposed patients were estimated, indepen-
dent of prior outcome history; and (2) time-to-first-ever-event analysis,
where hazards of first occurrence of outcome were estimated among
patients with no history of the outcome.
Propensity score adjustment was used as an analytic strategy to
reduce potential confounding as the result of imbalance between the
target and comparator cohorts in baseline covariates. The propensity
score is the probability of a patient being classified in the target
cohort vs the comparator cohort, given a set of observed covariates.
The propensity score was estimated using the predicted probability
from a regularized logistic regression model, fit with a Laplace prior
(LASSO) and the regularization hyperparameter selected through
cross-validation. Covariates used in the propensity score model
included demographics (gender, age, index year and month), prior con-
ditions, drugs, procedures and measurements observed during the
365 days prior to exposure, Charlson comorbidity index, the number
of distinct conditions, drugs, procedures and visits observed in the
prior 365 days and prior outcome history. Propensity score adjust-
ment was performed in 2 ways: (1) variable-ratio matching, where the
target cohort and comparator cohorts were matched with a maximum
ratio of 100 and using a caliper of 0.2 times the standard deviation of
the logit of the propensity score distribution; and (2) stratification,
where matched sets were derived from deciles of the propensity score
distribution across both cohorts. The final outcome model applied a
Cox proportional hazard model conditioned on the matched sets.11,12
For each outcome model, we reported the HR, 95% confidence inter-
val (CI), nominal P value and empirically calibrated P value.
Standardized mean difference was used as a metric to evaluate
the performance of propensity score adjustment. The propensity
score distribution of the target and comparator cohorts was plotted to
evaluate comparability of the 2 cohorts, scaling the plot to the prefer-
ence score to normalize for any imbalance in cohort size. The potential
for residual systematic error was examined by plotting the distribution
of estimates from negative control outcomes.
A large set of sensitivity analyses was performed to evaluate the
robustness of findings, the complete details of which are described in
the protocol. For each pairwise comparison of target and comparator
exposures (n = 7), for each outcome (n = 2) and for each database
(n = 4), there were 192 different analyses performed: 2 population
types (overall population, subpopulation with established cardiovascu-
lar disease) by 4 different prior exposure assumptions (no restrictions,
≥1 prior non-metformin AHA exposure, no prior non-metformin AHA
exposure, no prior exposure to comparator) by 6 time-at-risk windows
(on-treatment, intent-to-treat, on-treatment with delayed induction
and delayed lag, on-treatment without censoring at switch, on-
treatment with delayed indication and delayed lag without censoring
at switch, modified intent-to-treat) by 2 event types (first-ever event,
first post-index event) by 2 propensity score adjustment strategies
(variable ratio matching, stratification). In total, 10 752 effect esti-
mates were produced.
Data source-specific effect estimates were generated separately
for each comparison-outcome-analysis combination in the 4 different
populations, each of which reflects different patient compositions and
follow-up times and could potentially reveal different effects. Addi-
tionally, random-effects meta-analytic estimates were generated using
the DerSimonian-Laird and Hartung-Knapp-Sidik-Jonkman methods13
to pool evidence across the 4 databases for all comparison-outcome-
RYAN ET AL. 2587
analyses for which there was sufficient homogeneity (I2 < 40%). The
meta-analytic estimates provide a composite summary which can
serve as a useful supplement to the source-specific estimates that can
have greater precision than any source-specific estimate.14 Although
our analysis should be considered a form of individual patient-level
meta-analysis, we did not perform a “one-step” analysis because of
the fundamental differences in populations. In order to preserve the
internal validity of each population, we fit a propensity score model
for each database that was unique to the patient composition and
baseline characteristics of that database, and produced an effect esti-
mate within the follow-up time provided by each source. We specified
a priori that we would not produce a meta-analytic estimate when
substantial heterogeneity was observed, because the variability
reflects a potential violation of the random-effects assumption that
study estimates were drawn from the same underlying effect distribu-
tion and the use of a composite summary could be inappropriate.15
3 | RESULTS
All results have been made publicly available through an interactive
web-based application at http://data.ohdsi.org/AhasHfBkleAmputation.
This section summarizes the key findings across these results.
3.1 | Overall population
Table 1 summarizes the number of patients exposed, total time-at-risk
and the number of post-index outcomes observed within 4 cohorts of
interest, that is, new users of: (1) canagliflozin; (2) empagliflozin or
dapagliflozin (other SGLT2i); (3) all non-SGLT2i AHAs (any DPP-4i,
GLP-1 receptor agonist, TZD, SU, insulin or other AHA); and (4) select
non-SGLT2i AHAs (any DPP-4i, GLP-1 receptor agonist, or other
select AHA). Across the 4 databases, there were 142 800 new users
of canagliflozin, 110 897 new users of other SGLT2i, 460 885 new
users of all non-SGLT2i AHAs and 345 867 new users of select non-
SGLT2i. CCAE is the largest database, contributing 48% to 72% of
exposures in each cohort and 14% to 65% of the outcomes, while
MDCD is the smallest database, contributing 1% to 9% of exposures
and 2% to 21% of outcomes. The median time-at-risk for canagliflozin
new users ranged across databases from 61 to 104 days in the on-
treatment period, and from 284 to 562 days in the intent-to-treat
period. The incidence rate for BKLE amputation among new users of
canagliflozin in the overall population ranged from 1.0 to 5.0 events
per 1000 person-years in the on-treatment analysis, and from 1.5 to
4.5 events per 1000 person-years in the intent-to-treat analysis. The
incidence rate for HHF among new users of canagliflozin in the overall
population ranged from 0.9 to 5.5 events per 1000 person-years in
the on-treatment analysis, and from 2.1 to 11.8 events per 1000
person-years in the intent-to-treat analysis. Across all cohorts, MDCD
had the highest incidence rates for BKLE amputation, while MDCD
and MDCR had higher rates of HHF than CCAE and Optum.
Table 2 compares baseline characteristics of the target and com-
parator cohorts before and after propensity score matching across
each of the 4 databases. The composition of exposed populations var-
ied greatly among the databases; for example, the median age of
canagliflozin new users was 55 years in CCAE and Optum, 50 years in
MDCD and 70 years in MDCR. Across all databases, new users of
canagliflozin had a history of substantial prior use of other
non-metformin AHAs, including sitagliptin (29%-43%), glimepiride
(21%-29%), glipizide (20%-26%), pioglitazone (13%-25%) and insulin
glargine (14%-28%). Compared with all non-SGLT2i new users, cana-
gliflozin new users had a higher baseline prevalence of hyperlipidae-
mia and hypertension, and, accordingly, had a history of higher prior
use of agents acting on the renin-angiotensin system and lipid-
modifying agents. In MDCD, MDCR and Optum, prior to propensity
score matching, a greater proportion of patients in the all non-SGLT2i
cohort had a history of certain cardiovascular diseases (ie, heart fail-
ure, cerebrovascular disease and peripheral vascular disease) com-
pared to the canagliflozin cohort. Across all primary comparisons,
propensity score adjustment was able to balance all baseline covari-
ates, including cardiovascular disease history and amputation risk
factors, to a standardized difference <0.1. All primary comparisons
also passed the second diagnostic to evaluate the risk of residual bias
using negative control outcomes, as empirically calibrated statistics
were generally consistent with nominal values.
Table 3 shows results of the time-to-first-post-index HHF
analyses. The HR (95% CI) for the meta-analytic estimate for HHF
comparing new users of canagliflozin vs new users of all non-SGLT2i
within the on-treatment period was 0.39 (0.26-0.60). When compar-
ing new users of canagliflozin and new users of select non-SGLT2i
AHA in an on-treatment analysis, the HR (95% CI) was 0.58
(0.42-0.80). In the meta-analysis of all 4 databases, no difference in
risk of HHF was observed between new users of canagliflozin and
new users of other SGLT2i (HR [95% CI]: on-treatment, 0.90
[0.71-1.13] and intent-to-treat, 1.07 [0.95-1.20]).
Table 4 shows the results of the time-to-first-post-index BKLE
amputation analyses. The HR (95% CI) for the meta-analytic estimate
of BKLE amputation comparing new users of canagliflozin vs new
users of all non-SGLT2i was 0.75 (0.40-1.41) in the on-treatment anal-
ysis and 1.01 (0.93-1.10) in the intent-to-treat analysis. No differences
were observed between canagliflozin and other SGLT2i in any data-
base in the on-treatment or intent-to-treat analyses. The HR (95% CI)
for the meta-analytic estimate for BKLE amputation of canagliflozin vs
empagliflozin or dapagliflozin was 1.14 (0.67-1.93) in the on-
treatment analysis and 1.13 (0.99-1.29) in the intent-to-treat analysis.
Kaplan–Meier plots for the on-treatment analysis within each data-
base across the HHF and BKLE amputation outcomes are shown in
Figure 1.
3.2 | Subpopulation with established cardiovascular
disease
In the subpopulation with established cardiovascular disease, there
were 43 043 new users of canagliflozin, 31 011 new users of other
SGLT2i and 141 579 new users of all non-SGLT2i AHAs across the
4 databases. The median time-at-risk for canagliflozin new users with
established cardiovascular disease ranged across databases from 60 to
99 days in the on-treatment period, and from 325 to 581 days in the
intent-to-treat period. The incidence rates of BKLE amputation and
HHF in the subpopulation with established cardiovascular disease
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FIGURE 2 Forest plot of effect estimates for risk of amputation from all sensitivity analyses across databases and time-at-risk periods.
Abbreviations: CCAE, Truven MarketScan Commercial Claims and Encounters; MDCD, Truven MarketScan Multi-state Medicaid; MDCR, Truven
MarketScan Medicare Supplemental Beneficiaries; ITT, intent-to-treat; SGLT2i, sodium glucose co-transporter 2 inhibitors; HKSJ, Hartung-
Knapp-Sidik-Jonkman; DL, DerSimonian-Laird
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were generally observed to be approximately double those in the
overall new user cohorts.
The requirement for patients to have established cardiovascular
disease at baseline tended to make the populations more comparable
prior to propensity score adjustment, although some imbalances
remained. For example, compared to all non-SGLT2i new users, cana-
gliflozin new users with established cardiovascular disease had a lower
baseline prevalence of renal impairment and urinary tract disease. As
with the overall population, propensity score matching achieved bal-
ance across all baseline covariates with remaining standardized differ-
ences less than 0.1.
Effect estimates in the subpopulation with established cardiovas-
cular disease were consistent with those in the overall population
(Table S1). Effect estimates for HHF were consistent with the overall
population, with the comparison between new users of canagliflozin
and all non-SGLT2i yielding a statistically significant decreased risk
(on-treatment HR [95% CI], 0.44 [0.36-0.54]) (Table S2). However, no
difference was seen when comparing canagliflozin and other SGLT2i
(on-treatment HR [95% CI], 0.70 [0.30-1.63]). Of note, 75% of the
HHF events occurred in the 30% of the overall exposed population
with established cardiovascular disease.
The meta-analytic effect estimates for BKLE amputation in the
subpopulation with established cardiovascular disease were consis-
tent with findings in the overall population for new users of canagliflo-
zin vs new users of all non-SGLT2i in the on-treatment analysis
(HR [95% CI], 0.72 [0.34-1.51]) and the intent-to-treat analysis (HR [95%
CI], 1.14 [0.89-1.46]) (Table S3). When comparing canagliflozin and other
SGLT2i, there was no difference in either the meta-analysis or source-
specific estimates in the on-treatment analysis (meta-analysis HR [95%
CI], 1.08 [0.63-1.82]) or the intent-to-treat analysis (meta-analysis HR
[95% CI], 0.99 [0.68-1.46]).
3.3 | Sensitivity analyses
Figure 2 highlights the range of effect estimates for the risk of BKLE
amputation from all sensitivity analyses across databases and time-at-
risk periods. Across all analyses, there is no consistent evidence to
suggest any difference in risk of BKLE amputation between canagliflo-
zin and empagliflozin or dapagliflozin. Additionally, the comparison
between canagliflozin and all non-SGLT2i did not reveal any consis-
tent differences across databases. For both the canagliflozin vs non-
SGLT2i comparisons and the other SGLT2i vs non-SGLT2i compari-
sons, point estimates from the MDCD database indicated the poten-
tial for increased risk of BKLE amputation, although most estimates
were not statistically significant. Effect estimates in the overall popu-
lation were consistent with those in the subpopulation with estab-
lished cardiovascular disease.
Across all analyses, there is no evidence suggesting any difference
in risk of HHF between canagliflozin and empagliflozin or dapagliflozin
(Figure S1). For both the canagliflozin vs non-SGLT2i comparisons and
the other SGLT2i vs non-SGLT2i comparisons, SGLT2i showed a con-
sistent decreased risk of HHF relative to non-SGLT2i, with on-
treatment estimates showing a larger decrease in risk than that with
intent-to-treat analyses. As with BKLE amputation, effect estimates
for HHF in the overall population were consistent with those in the
subpopulation with established cardiovascular disease. For all analyses
where meta-analytic estimates were produced, the relative contribu-
tion of each source to the composite summary can be evaluated by
assessing the source-specific estimates and variances in the interac-
tive tool available at http://data.ohdsi.org/AhasHfBkleAmputation.
4 | DISCUSSION
OBSERVE-4D is a retrospective observational study representing the
largest and most comprehensive evaluation of the comparative effects
of canagliflozin and other SGLT2i to date. By comparing the real-
world experience of more than 140 000 patients initiating canagliflo-
zin with that of more than 100 000 new users of empagliflozin or
dapagliflozin and more than 460 000 new users of non-SGLT2i, we
can further characterize the potential benefits and harms of SGLT2i as
observed in routine clinical practice, to complement evidence gener-
ated by randomized trials and prior observational studies. The use of
4 different administrative claims databases representing multiple seg-
ments of the US health care system, including privately-insured popu-
lations, patients supported through state Medicaid programmes and
patients qualifying for national Medicare coverage, and the consis-
tency of results across these databases provide reassurance concern-
ing the generalizability of these real-world findings.
To our knowledge, this study represents the first analysis provid-
ing direct head-to-head comparative evidence for HHF or BKLE
amputation among individual drugs within the SGLT2i class. The ana-
lyses revealed a consistent pattern that suggests a class effect of
SGLT2i that reduces the risk of HHF relative to non-SGLT2i, both
overall and within the subpopulation with established cardiovascular
disease. Compared with new users of a DPP-4i or GLP-1 receptor
agonist, new users of canagliflozin had a lower risk of HHF in the on-
treatment and intent-to-treat analyses; the magnitude of the effect
was similar to that observed when comparing new users of empagli-
flozin or dapagliflozin and new users of non-SGLT2i. No difference in
HHF was observed in the head-to-head comparison of canagliflozin
and other SGLT2i within any database, subgroup or time-at-risk
period.
Neither canagliflozin nor the other SGLT2i showed a consistent
increased risk of BKLE amputation relative to non-SGLT2i in either
the overall population or within the subpopulation of patients with
established cardiovascular disease, although none of the analyses was
sufficiently powered to rule out the possibility of a modest effect. This
study also provided the first real-world comparison of the risk of BKLE
amputation with the use of canagliflozin relative to the use of other
SGLT2i, and found no statistically or clinically significant differences in
any database in either the on-treatment or intent-to-treat analyses.
HHF findings from this study are consistent with those from the
CANVAS Program and EASEL study for canagliflozin, from the EMPA-
REG OUTCOME study for empagliflozin and from the CVD-REAL
analysis of SGLT2i more broadly.1,3,5,8 Thus, the HHF result is a posi-
tive confirmatory finding; the consistency with clinical trial results
supports the internal validity and gives us a level of confidence that a
positive association could be successfully identified if present. Empiri-
cal calibration using 44 negative control outcomes provides support
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that our study design was unlikely to yield spurious associations with
false positive findings as the result of systematic or random error. It is
noteworthy that, in this study, the decreased risk of HHF was consis-
tent among all new users, as well as within the subpopulation with
established cardiovascular disease, even in light of the substantial
increase in baseline risk for patients with established cardiovascular
disease. It is also noteworthy that the effect estimates showed little
heterogeneity across databases, and were robust in a wide array of
sensitivity analyses. As expected and observed elsewhere, the magni-
tude of the effect is smaller in the intent-to-treat analyses than in the
on-treatment analyses, but it is nonetheless encouraging to see the
decrease in risk of HHF persist for some period, even after treatment
discontinuation or switching.
The comparative safety results for amputation are less concor-
dant with prior studies and warrant further scrutiny. An increased risk
of BKLE amputation with the use of canagliflozin was identified during
the CANVAS Program, which included patients with established car-
diovascular disease or high cardiovascular risk.1 In the CANVAS Pro-
gram, the increased risk of amputation began to emerge after 6 to
12 months of exposure.1 Increased risk of BKLE amputation was not
observed in any other studies across the phase 3/4 canagliflozin
development programme, although there was limited power to evalu-
ate risk in this population.7 In the CANVAS Program, the incidence
rates for amputation were 6.3 and 3.4 participants per 1000 patient-
years with canagliflozin and placebo, respectively, over a median
follow-up period of 126 weeks, and the HR (95% CI) was 1.97
(1.41-2.75).1 Despite differences in the observed HRs, the CIs for
the CANVAS Program and this study overlap. Compared with the
CANVAS Program, this study had a lower event rate (1-5 events per
1000 person-years, on-treatment and in the overall population) and a
shorter follow-up time (median, 60-100 days on-treatment). There-
fore, the current study had limited statistical power to detect differ-
ences in the 6 to 12-month period, the time at which amputation risk
began to emerge in the CANVAS Program, particularly in patients with
established cardiovascular disease. This discrepancy may be a limita-
tion, as a constant risk assumption may be violated and the potential
effect may require additional observation time before being detect-
able in a manner that is in line with the trial. On the other hand, it may
be revealing that real-world utilization of these drugs suggests that
the continuous exposure periods observed in clinical practice are
often shorter than the point at which the purported risk may take
effect. It is also possible that differences in the risk of BKLE amputa-
tion could be attributable to the composition of the patient popula-
tion, as patients who opt to participate in clinical trials may not always
reflect the general population. When attempting to reconcile these
results with those of the EASEL study, it is worth highlighting that the
EASEL population was older than that of CCAE, Optum and MDCD,
and the EASEL study had a slightly longer median follow-up time.8
Also, between the 2 cohorts, the EASEL study included only 17 events
in the on-treatment analysis and 35 events in the intent-to-treat anal-
ysis in the SGLT2i cohort,8 whereas this study included 33 on-
treatment and 163 intent-to-treat events among the cohort of new
users of canagliflozin with established cardiovascular disease across
the 4 databases. Relative to the EASEL study, this analysis also
conducted a larger array of sensitivity analyses to assess the robust-
ness of findings.
This study is subject to the limitations typical of observational
database research, including the potential for unmeasured confound-
ing and misclassification error that could bias the findings; however,
the use of negative controls suggests little to no systematic error.
Because the results were largely consistent across 4 databases, any
such source of systematic error could be attributable to artifacts asso-
ciated with the administrative claims process or consistent provider
channeling behaviour that would persist independent of insurance
coverage. No source record validation was performed to validate
exposures, outcomes or baseline covariates, and it is possible that dif-
ferential bias may have affected these attributes.
In this large observational study, treatment with canagliflozin was
associated with lower risk of HHF than non-SGLT2i, and the risk of
HHF with canagliflozin was comparable to that with other SGLT2i.
There were no observed differences in risk of BKLE amputation
among canagliflozin, other SGLT2i or all non-SGLT2i, in either the
overall population or the subpopulation with established cardiovascu-
lar disease. Overall, these results suggest that canagliflozin has a pro-
file similar to other SGLT2i as used in routine clinical practice. Patients
and providers may find this information useful when weighing the
comparative benefits against the potential risks in making treatment
decisions to support diabetes care.
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